Best of ASCO - 2014 Annual Meeting

 

Welcome

Leukemia/Lymphoma

Pediatric Oncology

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A novel association between GSTM1 null variant and anthracycline-induced cardiac dysfunction (ACD) in childhood cancer survivors (CCS): A COG ALTE03N1 report.

Purnima Singh

10030

A phase II trial testing interventions to shorten time to diagnosis and reduce abandonment of treatment of children with Burkitt lymphoma in Kenya.

Sandra Langat

10032

A randomized trial of a mercaptopurine (6MP) adherence-enhancing intervention in children with acute lymphoblastic leukemia (ALL): A COG ACCL1033 study.

Smita Bhatia

10007

AAML 1421, a phase I/II study of CPX-351 followed by fludarabine, cytarabine, and G-CSF (FLAG) for children with relapsed acute myeloid leukemia (AML): A Report from the Children’s Oncology Group.

Todd Michael Cooper

10003

Effect of intensification of induction II chemotherapy and liberalization of stem cell donor source on outcome for children with high risk acute myeloid leukemia: A report from the Children’s Oncology Group.

Richard Aplenc

10002

Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia/lymphoma: Results of DFCI 11-001.

Lynda M. Vrooman

10006

Gene expression signature associated with in vitro dexamethasone resistance and post-induction minimal residual disease in pediatric T-cell acute lymphoblastic leukemia.

Lauren K. Meyer

10033

Impact of asparaginase discontinuation on outcome in childhood ALL: A report from the Children’s Oncology Group (COG).

Sumit Gupta

10005

Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): A Children’s Oncology Group (COG) study.

Susan R. Rheingold

10008

Real-time sharing of comprehensive clinical genomics sequencing data in St. Jude Cloud.

Scott Newman

10019

Safety and activity of venetoclax in combination with high-dose cytarabine in children with relapsed or refractory acute myeloid leukemia.

Seth E Karol

10004

Sedation practices in pediatric ALL patients.

Bethany D. Nugent

e21500

Upfront azacitidine (AZA) in juvenile myelomonocytic leukemia (JMML): Interim analysis of the prospective AZA-JMML-001 study.

Charlotte M. Niemeyer

10031